1. Picroside I, picroliv and kutkoside possess the properties of antioxidants which appear to be mediated through activity like that of superoxide dismutase, metal ion chelators and xanthine oxidase inhibitors.
2. Picrosides I and II enhance basic fibroblast growth factor(bFGF)-, staurosporine- or dbc-mitogen-activated protein (MAP)-induced neurite outgrowth from PC12D cells, probably by amplifying a down-stream step of MAP kinase in the intracellular MAP kinase-dependent signaling pathway.
3. Picroside I exerts antiinflammatory activity in a variety of test models.
4. Picroside I , Kutkoside , and Kutkin may be the valuable anti-invasive drug candidates for cancer therapy by suppressing Collagenases and Gelatinases.
|CFN99852||3,4-O-Isopropylidene shikimic acid
1. 3,4-Oxo- isopropylidene-shikimic acid has significant anti-inflammatory effect which may be related to inhibiting the production of prostaglandin E2 and protecting free radical against oxidation.
2. 3,4-Oxo-isopropylidene-shikimic acid has protective effects on experimental colitis induced by trinitrobenzenesulfonic acid in rats, probably due to an antioxidant action.
3. 3,4-Oxo-isopropylidene-shikimic acid has anti-thrombosis effect, it inhibits thrombosis by anti-platelet-aggregation.
4. 3,4-Oxo-isopropylidene shikimic acid relieves the brain edema of rats subjected to MCAT by improving the energy metabolism and Na +, K +-ATPase activity in rat brain tissue.
5. 3,4-Oxo-isopropylidene-shikimic acid can inhibit adhesion of polymorphonuclear leukocyte to TNF-alpha-induced endothelial cells in vitro.
6. 3,4-Oxo-isopropylidene-shikimic acid has analgesic and antioxidant activities, it exhibits moderate antioxidant activity by scavenging the superoxide radical and hydroxyl radical with IC50 values of 0.214 and 0.450 ug/mL, respectively.
7. 3,4-Oxo-isopropylidene-shikimic acid has exhibited ameliorative effect on cognitive impairment in experimental animal models of dementia, it can promote adipogenesis by up-regulating expressions of C/EBP β, PPAR γ, C/EBP α, aP2 and FAS, and also stimulate adipokines during adipocyte differentiation, suggests that stimulation of adipokines and cognitive enhancing effect of 3,4-oxo-isopropylidene-shikimic acid have some relationship.
1. Magnolin has anti-inflammatory and antioxidative effects.
2. Magnolin can ameliorate the renal tubular necrosis, apoptosis, and the deterioration of renal function.
3. Magnolin reduces the renal oxidative stress, suppresses caspase-3 activity, and increases Bcl-2 expression in vivo and in vitro.
4. Magnolin might be a naturally occurring chemoprevention and therapeutic agent capable of inhibiting cell proliferation and transformation by targeting ERK1 and ERK2.
1. Harmine exerts its neuroprotective activity in neurological disorders.
2. Harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control.
3. Harmine is a hydrophobic drug with much adverse effects when used for treatment of liver cancer.
4. Harmine induces apoptosis and inhibits proliferation, migration and invasion of human gastric cancer cells, which may be mediated by down-regulation of COX-2 expression.
1. Ethyl gallate obviously decreases cell proliferation in MDA-MB-231 and MCF-7 cells in a dose- and time-dependent manner, exhibits cytotoxicity in a dose-dependent manner.
2. Ethyl gallate can inhibit the abilities of invasion of breast cancer in vitro by inhibiting the mRNA levels of MMP-9/MMP-2, phosphorylation of Akt and protein expression of NF-κB.
3. Ethyl gallate inhibits hydrogen peroxide signaling, may represent an alternative class of vasopressors for use in septic shock.
4. Ethyl gallate suppresses proliferation and invasion in human breast cancer cells by modulating the PI3K/Akt pathway, which may contribute to inhibiting their downstream targets such as NF-κB p-65, Bcl-2/Bax, and mRNA levels of MMP-2 and MMP-9 in breast cancer cells, could be used as potential antioxidants with safe therapeutic application in cancer chemotherapy.
5. Ethyl gallate, pentagalloylglucose, galloyl paeoniflorin, mudanpioside C and harpagoside can treat acute lung injury (ALI) mainly by reducing the total cells and infiltration of activated polymorphonuclear leukocytes (PMNs).